Catalyst Event
Bristol-Myers Squibb Co (BMY) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
5/29/2026, 12:00:00 AM
Announced positive Phase 3 SUCCESSOR-2 trial results for mezigdomide on 2026-05-29, showing a 52% reduction in disease progression risk; importance is Low as clinical trial results usually impact price by 1-4%.
Korean Translation
2026년 5월 29일 다발성 골수종 치료제 메지그도마이드의 임상 3상 긍정적 결과 발표. 임상 결과에 따른 주가 영향이 1-4%로 예상되어 중요도를 'Low'로 평가함.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target's Q2 2026 earnings release is set for August 19, 2026; low importance is estimated as the date announcement itself typically has a market impact of less than 5%, scheduled.
8/19/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
AST SpaceMobile Inc (ASTS) · Earnings Release
Q2 2026 earnings release and conference call for August 10, 2026, which is expected to have a medium impact by providing key financial updates, scheduled.
8/10/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Q2 2026 earnings release is scheduled for August 7, 2026; analysts forecast a significant increase in earnings due to higher oil prices and full integration of Hess assets. Market impact is estimated at Medium (5%) as earnings are a primary driver of stock volatility, scheduled.
8/7/2026, 12:00:00 AM
Akamai Technologies Inc (AKAM) · Earnings Release
Q2 2026 earnings release scheduled for 2026-08-06. Analysts forecast EPS of around $1.60 forecasted. High importance estimated due to the 26% price movement in the previous earnings release scheduled.
8/6/2026, 12:00:00 AM
Consolidated Edison Inc. (ED) · Earnings Release
Q2 2026 earnings release on 2026-08-06 is scheduled. Low importance is estimated as the primary market impact occurs on the release date, scheduled.
8/6/2026, 12:00:00 AM